SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-18527

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-18527-0.025mg
NBP3-18527-0.1mg
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

SARS-CoV, SARS-CoV-2

Applications

ELISA

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Llama Clone # T3P3F4

Format

Azide and BSA Free

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Spike Antibodies »

Product Specifications

Immunogen

SARS-CoV-2 variant Spike proteins

Clonality

Monoclonal

Host

Llama

Description

Recombinant Monoclonal Antibody - Llamabody(TM). Llama VHH domain containing a Myc-tag for detection and His-tag (MW ~ 15kDa)

Scientific Data Images for SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free

ELISA: SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free [NBP3-18527]

ELISA: SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free [NBP3-18527]

ELISA: SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free [NBP3-18527] - ELISA Validation with Trimers of SARS1 and SARS-CoV-2 Variants. Antibodies: SARS-CoV-2 Spike Antibody, NBP3-18527. A direct ELISA was performed using spike trimer proteins of both SARS1 and SARS-CoV-2 Variants (Delta, Omicron BA.1 and BA.5) as coating antigens at 1 ug/mL and NBP3-18527 antibody at 20-2000 ng/mL, followed by anti-cMyc-tag antibody at 1 ug/mL. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution. NBP3-18527 binds to all the spike trimers tested.

Applications for SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: Spike

The SARS-CoV-2 Spike protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The spike protein is the largest of the structural proteins, which also include the membrane (M), envelope (E), and nucleocapsid (N) proteins (1,2). The SARS-CoV-2 spike protein is a 1273 amino acid (aa) heterotrimeric class I fusion protein with each monomer having a theoretical molecular weight of approximately 180 kDa (1). The club-shaped spike protein contains several functional regions and domains including the S1 globular head region which contains the N-terminal receptor-binding domain (RBD) and the S2 stem region that contains the C-terminal fusion domain, two heptad regions, a transmembrane domain, and a cytoplasmic tail (1,2). The viral spike protein is critical for attachment of the virus with the host cell, resulting in fusion and virus entry into the cell (1,2). More specifically, the RBD of the spike protein is responsible for binding to the cell surface receptor angiotensin converting enzyme 2 (ACE2) (1,2). This spike-ACE2 interaction results in a conformational change permitting furin cleavage between the S1 and S2 domains and then cleavage at S2' by TMPRRS2, or another protease, allowing membrane fusion (1,2).

Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009

4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141

5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056

Long Name

Spike Protein

Alternate Names

S Protein

Gene Symbol

S

Additional Spike Products

Product Documents for SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 Spike Antibody (T3P3F4) - VHH - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.